Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Pulmatrix Inc (PULM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: PULM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.75% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.58M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 34820 | Beta 1.66 | 52 Weeks Range 1.68 - 10.40 | Updated Date 03/27/2025 |
52 Weeks Range 1.68 - 10.40 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate - | Actual -0.5438 |
Profitability
Profit Margin -122.46% | Operating Margin (TTM) -65066.67% |
Management Effectiveness
Return on Assets (TTM) -20.34% | Return on Equity (TTM) -70.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15058878 | Price to Sales(TTM) 3.15 |
Enterprise Value 15058878 | Price to Sales(TTM) 3.15 | ||
Enterprise Value to Revenue 1.93 | Enterprise Value to EBITDA 1.57 | Shares Outstanding 3652280 | Shares Floating 3652248 |
Shares Outstanding 3652280 | Shares Floating 3652248 | ||
Percent Insiders 0.65 | Percent Institutions 9.01 |
Analyst Ratings
Rating 4 | Target Price 10 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pulmatrix Inc
Company Overview
History and Background
Pulmatrix, Inc. was founded in 2003 and is a clinical stage biopharmaceutical company. It focuses on developing inhaled therapies to prevent and treat respiratory diseases using its iSPERSE technology.
Core Business Areas
- iSPERSE Technology: Pulmatrix's proprietary dry powder iSPERSE technology allows for the development of inhaled therapies with optimized drug delivery to the lungs.
- Pulmazole: An inhaled formulation of itraconazole for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with cystic fibrosis or asthma. Its current focus for regulatory approval.
- PUR1900: A formulation of iSPERSE for the treatment of fungal infections.
Leadership and Structure
The leadership team includes Robert Clarke (Chief Executive Officer). The organizational structure consists of departments responsible for research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- Pulmazole: Pulmazole is the company's lead clinical candidate for ABPA. While specific market share is not available, the ABPA market is estimated to grow. Competitors include current antifungal treatments.
- PUR1900: PUR1900 is a follow-on product candidate. No market share or revenue is currently available.
Market Dynamics
Industry Overview
The pharmaceutical industry focuses on respiratory disease therapeutics. It is driven by innovation and has many regulatory hurdles.
Positioning
Pulmatrix is positioned as a specialty pharmaceutical company. It focuses on inhaled therapies with a potentially differentiated technology.
Total Addressable Market (TAM)
The overall respiratory therapeutics market is substantial. Pulmatrix aims for a niche within fungal infections and ABPA. Specific TAM value dependent on regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary iSPERSE technology
- Focused on inhaled therapies
- Lead candidate in clinical trials
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No products currently on the market
- Small market cap
Opportunities
- Regulatory approval of Pulmazole
- Partnerships with larger pharmaceutical companies
- Expansion into new respiratory disease areas
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory requirements
- Generic versions if drug not patented correctly
- Delisting from NASDAQ
Competitors and Market Share
Key Competitors
- GILD
- NVS
- VTRS
Competitive Landscape
Pulmatrix competes with larger pharmaceutical companies that have established respiratory portfolios. Pulmatrix's advantage lies in its proprietary technology and focus on niche indications.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancement of clinical programs. Revenue is generated through grants and partnerships at this stage.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst estimates will vary widely.
Recent Initiatives: Monitor for clinical trial updates, partnerships, and financing announcements.
Summary
Pulmatrix is a clinical-stage biopharmaceutical company with a promising iSPERSE technology. Its future heavily relies on the success of Pulmazole's clinical trials and subsequent regulatory approval. The company needs to secure additional funding and navigate the competitive landscape dominated by larger pharmaceutical players. A failed trial could result in delisting or bankruptcy. Investors need to be aware of the financial risk.
Similar Companies
- GILD
- NVS
- VTRS
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (10-K, 10-Q)
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Financial data is subject to change and may not be perfectly accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulmatrix Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2014-03-21 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.pulmatrix.com |
Full time employees - | Website https://www.pulmatrix.com | ||
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.